Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > CD8+ TiLs and T-cell exhaustion

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Oct 04, 2024 8:07pm

117 Views

Post# 36254132

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:CD8+ TiLs and T-cell exhaustion

Bracelet-1 demonstrated 2 major findings: (1) PD-L1 with an activated Fc region result in T-cell exhaustion and (2) pelareorep is effective as a single agent monotherapy + paclitaxel vs paclitaxel alone. AND pelareorep promotes the upregulation of T-cell immune lymphocytes (TiLs) thus overcoming T-cell exhaustion, which ONC's GOBLET-1 Phase 2 cohort studies are showing when pelareorep is combined with the PD-L1 checkpoint inhibitor atezolizumab.

How many more times do I have to post this for you to understand?

<< Previous

Bullboard Posts

Next >>

E3 inches closer to Alberta's first lithium production plant